SCHEMBL8263300

SCHEMBL8263300

c1cncc(Nc2cccc(NCCc3c[nH]c4ccccc34)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 1/20 0.62
PTGS2 P35354 1/20 0.60
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
GBA1 P04062 1/20 0.53
CDK4 P11802 1/20 0.53
CCND1 P24385 1/20 0.53
AKT1 P31749 2/20 0.52
HTR1A P08908 2/20 0.51
HTR2A P28223 2/20 0.51
DRD2 P14416 1/20 0.51
HTR7 P34969 1/20 0.51
HTR6 P50406 1/20 0.51
POLB P06746 1/20 0.49
SLC2A1 P11166 1/20 0.49
RAD52 P43351 1/20 0.49
PAK4 O96013 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12845676 0.91 PTGS2 (0.62) SPRPTGS2KMT2AMEN1GBA1
SCHEMBL5947327 0.85 KMT2A (0.58) SPRPTGS2KMT2AMEN1CDK4
SCHEMBL12782524 0.82 HDAC3 (0.47) SPRPTGS2KMT2AMEN1AKT1
SCHEMBL8263301 0.79 PTGS2 (0.53) SPRPTGS2KMT2AMEN1GBA1
Serdemetan SCHEMBL3012498 0.78 HRH3 (0.58) PTGS2KMT2AMEN1HTR1AHTR2A
Serdemetan SCHEMBL29375950 0.78 HRH3 (0.58) PTGS2KMT2AMEN1HTR1AHTR2A
SCHEMBL12845625 0.78 HRH3 (0.56) SPRPTGS2KMT2AMEN1GBA1
SCHEMBL6599683 0.77 HTR2A (0.71) KMT2AMEN1HTR1AHTR2ADRD2
SCHEMBL12845514 0.77 HRH3 (0.54) PTGS2KMT2AMEN1HTR1AHTR2A
SCHEMBL12720717 0.77 SPR (1.00) SPRPTGS2KMT2AMEN1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404683-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICAL N.V. (BE) 2013-03-26 US disclosed
US-20110053937-A1 Inhibitors of the Interaction Between MDM2 and P53 LACRAMPE JEAN FERNAND ARMAND 2011-03-03 US disclosed
US-7834016-B2 Inhibitors of the interaction between MDM2 and p53 JANSSEN PHARMACEUTICA NV (BE) 2010-11-16 US disclosed
US-7834016-B2 Inhibitors of the interaction between MDM2 and p53 JANSSEN PHARMACEUTICA NV (BE) 2010-11-16 US disclosed
US-20080039472-A1 Inhibitors of the Interaction Between Mdm2 and P53 JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-14 US disclosed
US-20080039472-A1 Inhibitors of the Interaction Between Mdm2 and P53 JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-14 US disclosed
WO-2006032631-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053937-A1 Inhibitors of the Interaction Between MDM2 and P53 TP53, MDM2, TP53BP1 SPR 971/4885PTGS2 3159/4885KMT2A 2688/4885
US-20080039472-A1 Inhibitors of the Interaction Between Mdm2 and P53 TP53, MDM2, TP53BP1 SPR 971/4885PTGS2 3159/4885KMT2A 2688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.